[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1039 Introduced in House (IH)]

<DOC>






118th CONGRESS
  2d Session
H. RES. 1039

  Recognizing the significance of Charcot-Marie-Tooth disease and the 
   need for robust funding of the National Institute of Neurological 
       Disorders and Stroke at the National Institutes of Health.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 29, 2024

  Mr. Gottheimer (for himself and Mr. Bacon) submitted the following 
 resolution; which was referred to the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
  Recognizing the significance of Charcot-Marie-Tooth disease and the 
   need for robust funding of the National Institute of Neurological 
       Disorders and Stroke at the National Institutes of Health.

Whereas Charcot-Marie-Tooth disease (CMT) causes damage to the peripheral 
        nerves, which transmit information and signals from the brain and spinal 
        cord to the rest of the body, and can also directly affect the nerves 
        that control the muscles;
Whereas it is estimated that 126,000 individuals in the United States have CMT 
        and 2,600,000 people worldwide;
Whereas nearly all cases of CMT are inherited;
Whereas the specific gene that causes CMT has not yet been identified;
Whereas there are many different types of CMT, including CMT4B3; and
Whereas, despite its impact, Federal funding for CMT research was actually less 
        in 2022 than in 2021: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) recognizes that Charcot-Marie-Tooth disease is a 
        significant disease impacting thousands of Americans and 
        millions around the world;
            (2) expresses that Charcot-Marie-Tooth disease should 
        receive robust funding for research to ensure all is being done 
        to study this disease at the National Institute of Neurological 
        Disorders and Stroke within the National Institutes of Health; 
        and
            (3) expresses the need to continue to invest in research 
        efforts to tackle Charcot-Marie-Tooth disease and other rare 
        diseases that currently have no cure.
                                 <all>